Nautilus Biotechnology Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Nautilus Biotechnology Inc.
- Former names
- ARYA Sciences Acquisition Corp III
- Ownership
- Public
- Status
- Active
- SIC code
- 3826 — Laboratory Analytical Instruments
- Headquarters city
- Seattle
- Headquarters state / province
- Washington
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- NAUT
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001808805
- EIN
- 98-1541723
Board of directors
-
Farzad Nazem · DirectorSince 2023
- Since 2023
-
Karen Akinsanya · DirectorSince 2023
-
Matthew L. Posard · DirectorSince 2023
-
Matthew S. McIlwain · DirectorSince 2023
-
Melissa B. Epperly · DirectorSince 2023
-
Michael Seth Altman · DirectorSince 2023
-
Parag Mallick · Director · Chief ScientistSince 2023
-
Sujal M. Patel · Director · CEO, President, and SecretarySince 2023
-
Vijay Satyanand Pande · DirectorSince 2023
Chief executives
Sujal M. Patel
· CEO, President, and Secretary
Dates unknown
Director election results
Annual meeting of June 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
96.6%
-
96.7%
Board connections
5 of this board's directors also sit on 10 other boards.
- via Joseph Edelman and Michael Seth Altman
- via Joseph Edelman
- via Vijay Satyanand Pande
- via Matthew L. Posard
- via Joseph Edelman
- via Joseph Edelman
- via Joseph Edelman
- via Joseph Edelman
- via Melissa B. Epperly
- via Joseph Edelman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $71,210
- 2 purchases by 2 insiders
- Sold, last 12 months
- $11,750,000
- 2 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 2, 2026 | AH Bio Fund II, L.P. 10% owner | Open-market sale | −4,615,974 | $2.35 | $10,847,539 |
| Jun 2, 2026 | AH Bio Fund II, L.P. 10% owner | Open-market sale | −384,026 | $2.35 | $902,461 |
| Mar 4, 2026 | Sujal M. Patel Director, Officer (CEO, President, and Secretary), 10% owner | Open-market purchase | +25,000 | $2.61 | $65,250 |
| Nov 6, 2025 | Suzuki Kentaro Officer (Chief Marketing Officer) | Open-market purchase | +4,000 | $1.49 | $5,960 |
| Sep 8, 2025 | Sujal M. Patel Director, Officer (CEO, President, and Secretary), 10% owner | Open-market purchase | +83,500 | $0.68 | $56,780 |
| Sep 5, 2025 | Sujal M. Patel Director, Officer (CEO, President, and Secretary), 10% owner | Open-market purchase | +116,500 | $0.67 | $78,055 |
| Sep 4, 2025 | Murphy Matthew B. Officer (General Counsel) | Open-market purchase | +20,000 | $0.64 | $12,800 |
| May 29, 2025 | Mowry Anna Officer (CFO and Treasurer) | Open-market purchase | +15,000 | $0.77 | $11,550 |
| May 12, 2025 | Parag Mallick Director, Officer (Chief Scientist), 10% owner | Open-market purchase | +1,500 | $0.73 | $1,095 |
| May 8, 2025 | Parag Mallick Director, Officer (Chief Scientist), 10% owner | Open-market purchase | +12,000 | $0.73 | $8,760 |
| Mar 20, 2025 | Sujal M. Patel Director, Officer (CEO, President, and Secretary), 10% owner | Open-market purchase | +23,933 | $1.00 | $23,933 |
| Mar 19, 2025 | Sujal M. Patel Director, Officer (CEO, President, and Secretary), 10% owner | Open-market purchase | +53,300 | $0.99 | $52,767 |
| Sep 23, 2024 | Godwin Mary E. Officer (Senior VP, Operations) | Option exercise | +47,031 | $0.46 | $21,634 |
| Sep 23, 2024 | Godwin Mary E. Officer (Senior VP, Operations) | Open-market sale | −47,031 | $2.87 | $134,979 |
| Sep 17, 2024 | Godwin Mary E. Officer (Senior VP, Operations) | Option exercise | +35,000 | $0.46 | $16,100 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.